GSK (NYSE:GSK) Downgraded to “Neutral” at UBS Group

UBS Group lowered shares of GSK (NYSE:GSKFree Report) from a buy rating to a neutral rating in a report published on Monday morning, MarketBeat Ratings reports.

Several other research analysts have also weighed in on GSK. The Goldman Sachs Group started coverage on GSK in a research report on Thursday, May 30th. They issued a neutral rating and a $47.00 target price on the stock. Berenberg Bank raised GSK to a strong-buy rating in a research report on Thursday, June 20th. Jefferies Financial Group increased their target price on GSK from $52.50 to $53.00 and gave the stock a buy rating in a research report on Tuesday, July 2nd. Finally, Citigroup raised GSK to a strong-buy rating in a research report on Monday, June 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $50.00.

Read Our Latest Analysis on GSK

GSK Trading Down 0.1 %

Shares of GSK stock opened at $38.56 on Monday. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The firm has a market cap of $79.91 billion, a PE ratio of 13.97, a P/E/G ratio of 1.17 and a beta of 0.64. The business’s fifty day moving average is $42.07 and its two-hundred day moving average is $41.31. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK (NYSE:GSKGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The company had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. Analysts anticipate that GSK will post 4.1 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a $0.3762 dividend. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a yield of 3.90%. The ex-dividend date is Thursday, May 16th. GSK’s dividend payout ratio is currently 53.26%.

Institutional Trading of GSK

Several large investors have recently added to or reduced their stakes in GSK. Ameriprise Financial Inc. increased its holdings in GSK by 3.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,270,782 shares of the pharmaceutical company’s stock valued at $46,091,000 after purchasing an additional 43,753 shares in the last quarter. Toroso Investments LLC increased its holdings in GSK by 1.6% in the 3rd quarter. Toroso Investments LLC now owns 28,575 shares of the pharmaceutical company’s stock valued at $1,036,000 after purchasing an additional 444 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in GSK by 69.0% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 142,120 shares of the pharmaceutical company’s stock valued at $5,152,000 after purchasing an additional 58,022 shares in the last quarter. Morgan Stanley increased its holdings in GSK by 2.1% in the 3rd quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock valued at $273,744,000 after purchasing an additional 156,480 shares in the last quarter. Finally, Creative Planning grew its stake in shares of GSK by 21.4% during the third quarter. Creative Planning now owns 200,059 shares of the pharmaceutical company’s stock valued at $7,252,000 after acquiring an additional 35,231 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Featured Stories

Analyst Recommendations for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.